Patients with lung cancer had higher CEA levels compared to patients without cancer, with more than 20% of stage I–III and the majority of stage IV cancer patients having levels >7.5 ng/ml, while only ~4% of non-cancer patients fell above this threshold12,15,34 (p < 0.001)(Supplementary Fig. 8). This evidence concerns the gene CEACAM5 and cancer.